The above multi-omics combined analysis implied that NCAPG2 might pose a great potential as a novel prognostic and immune infiltration marker or therapeutic target for carcinomas, whereas the current studies are limited by the lack of in-depth experiments to verify its specific immune infiltration relationship with the TME, and the insufficiency of verification of the relevance of the current immunotherapeutic targets. The gene discussed is NCAPG2; the disease is carcinoma.